Five FDA records link AtriCure, Inc. of 7555 Innovation Way, Mason, Ohio, to cardiovascular device submissions: four premarket approval records and one 510(k). The collection spans an original Synergy approval in 2011, an EPi-Sense approval in 2021, two 2026 thirty-day notices for sterilization process changes, and a 2026 clearance for a smaller AtriClip device. The counts describe the supplied filings as of the snapshot date, not company sales, total portfolio or safety performance. [1][2][4]
Ablation systems under premarket approval
The AtriCure Synergy Ablation System holds approval P100046, decided December 14, 2011, under product code OCM and the generic name surgical cardiac ablation device for treatment of atrial fibrillation. The approval statement describes ablation of cardiac tissue for persistent or longstanding persistent atrial fibrillation in patients undergoing open concomitant coronary artery bypass grafting and/or valve replacement or repair. The filing carries an expedited review flag and docket number 11M-0910. [5]
The EPi-Sense Guided Coagulation System holds approval P200002, received January 2, 2020 and decided April 28, 2021, also under product code OCM. Its approval statement covers treatment of symptomatic longstanding persistent atrial fibrillation when augmented in a hybrid procedure with an endocardial catheter listed in the instructions for use, in patients refractory or intolerant to at least one Class I and/or III antiarrhythmic drug, and in whom expected benefit from rhythm control outweighs known risks of a hybrid procedure. [4]
2026 supplements for sterilization process changes
Two thirty-day notices were decided September 24, 2026, both received August 25, 2026. P100046/S021 covers the Synergy Ablation System and P200002/S015 covers the EPi-Sense ST Coagulation System. Each lists the supplement reason as a process change involving manufacturer, sterilizer, packager or supplier, with an alternate sterilization cycle noted in the applicant-statement field. Both sit under the Cardiovascular advisory committee and were not expedited. [2][3]
The AtriClip FLEX-Mini clearance
K263319 cleared October 21, 2026 as substantially equivalent for the ACHM30 AtriClip FLEX-Mini LAA Exclusion System, received September 21, 2026. The FDA letter places it under 21 CFR 878.4300, implantable clip, Class II, with product codes PZX and FZX, reviewed by the Division of Circulatory Support, Structural, and Vascular Devices. The 510(k) database entry lists the classification as Left Atrial Appendage Clip, Implantable. [1][6][8]
AtriCure's own brochure states that the LAA Exclusion System is indicated for exclusion of the heart's left atrial appendage under direct visualization and in conjunction with other cardiac surgical procedures. The same brochure describes the FLEX-Mini as a disposable device with a handle, shaft, suture anchors, shaft rotation knob and a deployment end effector containing the AtriClip Mini, available in 35, 40, 45 and 50 mm lengths. [10]
Company-published device features
AtriCure's healthcare-professional page describes the AtriClip FLEX-Mini as a closed-ended surgical left atrial appendage management device and states that it provides mechanical and electrical isolation of the appendage, with footnoted references on the page. The page also lists magnetic resonance conditions, including normal operating mode and a whole-body averaged SAR limit of 2 W/kg for 60 minutes of continuous RF exposure, and notes that the implant produces an imaging artifact. [7]




